NVS logo

Novartis AG

NVS
Healthcare|Drug Manufacturers - General|CH
$162.55
+0.62 (+0.38%)
DCF Value
$269.57
Graham Number
$48.20
Cash / Share
$4.75

Clinical Trials (527)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT07488520
Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire
Sickle Cell Disease (SCD)
P4
Recruiting120Open-label—
NCT05161195
Roll-over Study to Allow Continued Access to Ribociclib
Metastatic Breast Cancer
P4
Active134Open-labelRibociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
NCT06941792
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
Coronary Heart Disease
P4
Active1,590RCT, Open-labelinclisiran sodium injection
NCT07489573
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
P4
Recruiting36Open-labelSecukinumab
NCT07034690
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
Atherosclerotic Cardiovascular Disease
P4
Recruiting326RCT, Open-label—
NCT04111978
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms
P3
Recruiting540RCT, Double-blindLetrozole 2.5mg
NCT05739383
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
P3
Active14,012RCT, Double-blindInclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
NCT07440290
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Haematological Malignancy, Malignant Neoplasm
P2P3
Recruiting30Open-labelDabrafenib, Trametinib
NCT04765657
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
Hypercholesterolemia
P3
Active345RCT, Double-blindinclisiran sodium, Placebo
NCT07225504
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis (SPMS)
P3
Recruiting1,275RCT, Double-blindRemibrutinib (blinded), Placebo, Remibrutinib (Open label)
NCT04573478
Atrasentan in Patients With IgA Nephropathy
IgA Nephropathy, Immunoglobulin A Nephropathy
P3
Active404RCT, Double-blindAtrasentan, Placebo, Zigakibart
NCT07498335
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
P3
Recruiting28Open-labelDrug: Atrasentan
NCT02925234
The Drug Rediscovery Protocol (DRUP Trial)
Cancer, Tumors
P2
Recruiting1,550Open-labelPanitumumab, Olaparib, Dabrafenib, Nilotinib, Trametinib, Erlotinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib, Regorafenib, Nivolumab, Afatinib, Dabrafenib and trametinib, Ribociclib, Lenvatinib, Pembrolizumab, Durvalumab, Rucaparib, Axitinib, Palbociclib, Crizotinib, Sunitinib, Cabozantinib, Abemaciclib, Alectinib, Atezolizumab and Bevacizumab, Ipilimumab and nivolumab, Entrectinib, Talazoparib, Dacomitinib, Lorlatinib, Erdafitinib, Alpelisib, Niraparib, Pemigatinib, Selpercatinib, Tepotinib
NCT01872260
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Breast Cancer
P1P2
Active259RCT, Open-labelLEE011, Letrozole, BYL719
NCT03206086
Eltrombopag for Fanconi Anemia
Fanconi Anemia
P2
Active25Open-labelEltrombopag
NCT05180695
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
P1P2
Active47Open-labelPazopanib, HDM201
NCT06004661
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
P2
Active23Open-labelAAA617, 68Ga-PSMA-11
NCT07048197
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
P1P2
Active27Open-labelRapcabtagene autoleucel
NCT07549646
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies
P2
Recruiting45Open-labelTrametinib
NCT03090165
Ribociclib and Bicalutamide in AR+ TNBC
Triple Negative Breast Cancer
P1P2
Active37Open-labelribociclib, ribociclib, Bicalutamide
NCT02881242
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
P2
Active14Open-labelTrametinib
NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
P1P2
Recruiting300Open-labelTulmimetostat, Enzalutamide
NCT07431177
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Non-segmental Vitiligo
P2
Recruiting210RCT, Double-blindGIA632, Placebo
NCT07226986
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
P1P2
Recruiting123Open-labelAMO959, Enzalutamide, Abiraterone
NCT02858921
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Melanoma
P2
Active60RCT, Open-labelDabrafenib, Trametinib, Pembrolizumab
NCT05750628
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Uncomplicated Plasmodium Falciparum Malaria
P2
Recruiting327RCT, Open-labelINE963, KAE609 (Cipargamin), SoC (Coartem), KLU156
NCT07136428
Asciminib in HER2+ Breast Cancer Brain Metastases
HER2+ Metastatic Breast Cancer
P1P2
Recruiting42Open-label—
NCT03591510
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
FLT3-mutated Acute Myeloid Leukemia
P2
Active22Open-labelMidostaurin, Fludarabine, Cytarabine, Daunorubicin or idarubicin, Mitoxantrone, Etoposide
NCT05445843
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
P2
Active95Open-labelJDQ443
NCT05469360
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Alzheimer Disease, Mild Cognitive Impairment
P1
Active38RCT, Double-blindNIO752, NIO752, Matching placebo, NIO752, NIO752, NIO752, Matching placebo
NCT06379217
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Metastatic Neuroendocrine Prostate Cancer
P1
Active31Open-label[68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide
NCT06155500
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
Sickle Cell Disease
P1
Active4Open-labelOTQ923
NCT07340138
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF)
P1
Active3Open-labelPelabresib, Ruxolitinib
NCT07443137
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Large-cell Lymphoma
P1
Recruiting20Open-labelRapcabtagene autoleucel (YTB323)
NCT07644364
HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension
Elevated Blood Pressure, Hypertension
P1
Recruiting64RCT, Double-blindHJB647, Placebo
NCT07422610
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Advanced Malignancies and Hepatic Impairment
P1
Recruiting24Open-labelpelabresib
NCT03349801
Development of Novel Clinical Endpoints in Intermediate AMD
Age Related Macular Degeneration (AMD)
Active718——
NCT04671693
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
Late Effects, Testicular Germ Cell Tumor Mixed
N/A
Active500Open-label—
NCT04497285
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer
Metastatic Breast Cancer
Active600——
NCT05009160
DreaMS - Validation Study 1
Multiple Sclerosis
Active300——
NCT05017142
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Optic Neuritis, Transverse Myelitis
Recruiting500——
NCT05918666
National Register of Actionable Mutations
Solid Tumours in Advanced Stages
Active2,098——
NCT03577197
Southeast Netherlands Advanced Metastatic Breast Cancer Registry
Advanced Breast Cancer, Metastatic Breast Cancer
Recruiting7,000——
NCT02622581
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic
Recruiting14,500——
NCT07779460
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
Multiple Sclerosis
Recruiting7,466——
NCT05344469
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Recruiting800——
NCT07378969
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy
Secondary Malignancies of T-cell Origin
Recruiting30——
NCT07543419
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
Hidradenitis Suppurativa
Recruiting250——
NCT04666272
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
Melanoma
Active78—dabrafenib, trametinib
NCT07758270
Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
Multiple Sclerosis (MS) - Relapsing-remitting
Recruiting15—Remibrutinib, Ocrelizumab (US)
NCT06770543
Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
Primary Hypercholesterolemia or Mixed Dyslipidemia
Recruiting1,500——
NCT06643936
E3 Diabetes - Closing the Gap in Diabetes Control
Type 2 Diabetes
N/A
Active150RCT, Double-blind—
NCT07549516
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
Leukemia, Chronic Myeloid
Recruiting380——
NCT07594587
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
Graft-Versus-Host Disease
Recruiting395——
NCT07465666
A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Hypertension
Recruiting500——
NCT03958136
Clinico-biological Data Collection Study of Metastatic Breast Cancer
Breast Cancer
N/A
Active289Open-labelBiomarkers blood, urine and microbiota samples
NCT06287268
Revolade Tablets Specified Drug-use Survey
Aplastic Anemia
Recruiting10——
NCT06785779
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
Hidradenitis Suppurativa (HS)
Recruiting77——
NCT01521715
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell
P4
Completed44Open-labelPazopanib
NCT01266837
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
Metastatic Renal Cell Carcinoma, Failure of Exactly One Prior VEGF-targeted Therapy
P4
Completed64Open-labelEverolimus
NCT02248571
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast
P4
Completed85RCT, Open-labelBevacizumab, Capecitabine, Everolimus, Exemestane
NCT00170859
Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
Heart Transplantation
P4
Completed—RCT, Open-labelEverolimus
NCT00332462
A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients
Liver Transplantation
P4
Completed34Open-labelCyclosporine (Sandimmun® i.v.), Cyclosporine (Sandimmun® Optoral)
NCT01206088
Tasigna in Glivec-resistant or Intolerant Patients in CML
CML, Nilotinib
P4
Completed93Open-labelnilotinib
NCT00760266
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
Hypertension
P4
Completed451RCT, Double-blindAliskiren, Hydrochlorothiazide
NCT01935128
Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction
Renal Transplant
P4
Completed55Open-labelArm 1 Everolimus/Reduced dose tacrolimus
NCT01518101
Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications
Type 2 Diabetes
P4
Completed62RCT, Open-labelVildagliptin/ Metformin, Liraglutide, Metformin
NCT01464229
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Major Depressive Disorder
P4
Completed20RCT, Double-blindIloperidone, Placebo
NCT00691873
Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
Asthma
P4
Completed14RCT, Double-blindPlacebo, Xolair
NCT02069886
Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia
Thalassemia (Transfusion Delendent)
P4
Withdrawn—Open-labeldeferasirox
NCT00660309
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
P4
Completed45RCT, Open-labelAliskiren, Irbesartan, Captopril
NCT00776009
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
Attention-Deficit/Hyperactivity Disorder (ADHD)
P4
Completed165RCT, Double-blindDex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
NCT00965094
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients
Chronic Renal Failure
P4
Completed36RCT, Open-labelEverolimus, Tacrolimus (FK506), Basiliximab, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids
NCT00238966
Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil
Renal Transplantation
P4
Completed187Open-labelEnteric-Coated Mycophenolate Sodium (EC-MPS)
NCT01056822
Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.
Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft
P4
Completed89RCT, Open-label1, 2
NCT00738257
A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.
Bone Loss
P4
Completed126RCT, Open-labelPamidronate
NCT02976194
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
P4
Unknown28Open-labelranibizumab
NCT00942994
Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension
Hypertension
P4
Completed412RCT, Double-blindAliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
NCT01211327
Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda
Vernal Keratoconjunctivitis
P4
Completed366RCT, Double-blindCyclosporine A, Dexamethasone
NCT01490840
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Fatigue in Multiple Sclerosis
P4
Terminated178Open-label—
NCT00772577
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
Hypertension
P4
Completed386RCT, Double-blindAliskiren Hydrochlorothiazide, Ramipril
NCT00302705
Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose
Hypertension
P4
Completed150RCT, Open-labelValsartan, Enalapril
NCT00845871
Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
Transfusional Hemosiderosis
P4
Completed65Open-labeldeferasirox:
NCT02779257
Pasireotide Treatment for Neuroendocrine Tumor
Gastro-enteropancreatic Neuroendocrine Tumor
P4
Withdrawn—Open-labelPasireotide, Diazoxide
NCT00154297
Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients
Renal Transplantation
P4
Completed139RCT, Open-labelEverolimus (RAD001)
NCT00171574
Antiproteinuric Effect of Valsartan and Lisinopril
Hypertension, Diabetic Nephropathy
P4
Completed124RCT, Double-blindValsartan, Valsartan plus HCTZ, Lisinopril
NCT01169701
24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
Renal Transplant
P4
Completed71RCT, Open-labelEverolimus, Tacrolimus, Mycophenolic acid (MPA)
NCT01666197
Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain
Ankle Sprain
P4
Completed100RCT, Double-blinddiclofenac potassium 25 mg tablet, placebo
NCT00948766
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
Alzheimer's Disease
P4
Completed716RCT, Double-blindRivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo
NCT00241046
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
Metastatic Breast Cancer
P4
Terminated13Open-labelLetrozole
NCT00909324
Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery
Dry Eye
P4
Completed170RCT, Open-labelPre-LASIK 0.3% hypromellose, Post-LASIK 0.3% hypromellose
NCT02123108
Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation
Liver Transplantation
P4
Completed59RCT, Open-labelBasiliximab, Tacrolimus, Tacrolimus, Mycophenolic Acid
NCT00439738
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
Hypertension
P4
Completed412RCT, Double-blindHCTZ + Amlodipine, Valsartan/HCTZ
NCT00241085
Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus
PROTEINURIA, Hypertension
P4
Completed392RCT, Double-blindvalsartan
NCT00115115
Donor Dopamine and Initial Graft Function
Kidney Transplantation, ESRD
P4
Completed487RCT, Open-labelDopamine infusion to brain dead organ donors
NCT02254668
Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography
Intimal Proliferation, Immunosuppression
P4
Unknown278RCT, Open-label—
NCT00673218
The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils
Allergy
P4
Unknown25RCT, Double-blindPlacebo, Xolair
NCT00280540
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
Hypertension
P4
Completed648RCT, Double-blindValsartan/Hydrochlorothiazide
NCT00639691
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy
Asthma
P4
Completed48Open-labelomalizumab
NCT02366468
Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
Diabetic Retinopathy
P4
Completed135RCT, Single-blindranibizumab 0.5 mg
NCT01529619
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Alzheimer's Disease
P4
Completed52Open-labelRivastigmine transdermal patch
NCT01578330
A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
Multiple Sclerosis, Relapsing-Remitting
P4
Completed42Open-labelFingolimod
NCT04774926
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
Neovascular Age-related Macular Degeneration
P4
Completed122Open-labelBrolucizumab
NCT01218035
Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis
Hip Osteoarthritis
P4
Completed49RCT, Double-blindzoledronic acid
NCT02546674
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
Chronic Myeloid Leukemia
P4
Completed171Open-labelNilotinib
NCT05080218
COVID-19 VaccinE Response in Rheumatology Patients
Rheumatoid Arthritis, Psoriatic Arthritis
P4
Completed841RCT, Open-labelUpadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
NCT01043874
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase
P4
Completed45Open-labelNilotinib
NCT00658333
A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms
Renal Transplantation
P4
Terminated30RCT, Double-blindEnteric-coated Mycophenolate Acid (EC-MPA), Mycophenolate Mofetil (MMF), Placebo MMF, Placebo EC-MPA
NCT01541189
Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.
Hypertension
P4
Completed200Open-labelValsartan
NCT02842749
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
Pancreatic Neuroendocrine Tumors
P4
Completed61Open-labeleverolimus
NCT00749515
Pilot Study for Patients With Poor Response to Deferasirox
Transfusion-dependent Hemachromatosis, Thalassemia Major
P4
Completed15Open-labelDeferoxamine, Deferasirox
NCT02178540
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
Cystic Fibrosis
P4
Completed45Open-labelPlacebo
NCT01196546
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus
P4
Completed161Open-labelvildagliptin/metformin
NCT00509990
Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting
Atopic Dermatitis
P4
Completed200Open-labelPimecrolimus
NCT00035997
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
Prostate Cancer
P4
Completed261Open-labelZometa
NCT01106482
An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE
Tick Borne Encephalitis (TBE)
P4
Completed126RCT, Open-label—
NCT00150059
Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis
Atopic Dermatitis
P4
Completed—Open-labelPimecrolimus Cream 1%
NCT02344472
Detect V / CHEVENDO (Chemo vs. Endo)
Metastatic Breast Cancer
P3
Unknown271RCT, Open-labelpertuzumab, Trastuzumab, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, nab-Paclitaxel, eribulin, leuprorelin, goserelin
NCT04828161
A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
COVID-19
P2P3
Terminated407RCT, Double-blindensovibep, Placebo
NCT00433589
Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
Breast Cancer
P3
Completed6,600RCT, Open-labelanthracycline-based, docetaxel and capecitabine, tamoxifen, Letrozole
NCT00219739
STI571 ProspectIve RandomIzed Trial: SPIRIT
Chronic Myeloid Leukemia
P3
Completed789RCT, Open-labelImatinib mesylate 400 mg, Imatinib mesylate 600 mg, Imatinib 400 mg + Peg-Interferon, Imatinib mesylate 400 mg + Cytarabine
NCT01028092
mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation
Renal Transplant
P3
Completed327RCT, Open-labelAnti R-IL2 + Cyclosporine, Thymoglobulin + Everolimus, Anti R-IL2 + Cyclosporine then Everolimus
NCT01803763
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
Chronic Urticaria, Chronic Idiopathic Urticaria
P2P3
Completed30RCT, Double-blindOmalizumab (Xolair), Placebo
NCT03462251
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line
Breast Cancer, Hormone Receptor Positive Tumor
P3
Completed41RCT, Open-label—
NCT01110889
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder
Major Depressive Disorder
P3
Completed582RCT, Double-blindAgomelatine (AGO178C), Agomelatine (AGO178C), Placebo
NCT00344110
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Hypertension
P3
Completed768RCT, Double-blindAliskiren
NCT00735410
Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009
Seasonal Influenza, Vaccine
P3
Completed134RCT, Open-labelSeasonal Influenza Vaccine
NCT03917459
COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
Heart Failure, Heart Failure, Systolic
P3
Completed27RCT, Double-blindLCZ696, Enalapril matching placebo, Enalapril, LCZ696 matching placebo
NCT03386474
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
Neovascular Age-related Macular Degeneration
P3
Completed151Double-blindBrolucizumab 6 mg, Aflibercept 2 mg
NCT00098046
Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
Chickenpox, Herpes Zoster
P3
Completed76Open-labelfamciclovir
NCT01586962
Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI
Upper Respiratory Infections
P3
Completed56Open-labelIFF flavor 316 282, Paracetamol, Pseudoephedrine
NCT01764841
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Bronchiectasis
P3
Completed416RCT, Double-blindCiprofloxacin DPI (BAYQ3939), Placebo
NCT01257451
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
Type 2 Diabetes Mellitus
P3
Completed431RCT, Double-blindVildagliptin, Placebo
NCT01617681
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
Pediatric Hypertension With or Without CKD
P3
Completed127RCT, Double-blindVAL489, VAL489 matching placebo
NCT05350072
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
Sjogren Syndrome
P3
Completed275RCT, Double-blindVAY736
NCT04206761
Investigating the Effects of QVM149 on MRI Ventilation Defects
Asthma
P3
Withdrawn—RCT, Open-labelQVM149, High Dose Dual Therapy (ICS/LABA)
NCT00005073
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
Prostate Cancer
P3
Terminated544RCTzoledronic acid
NCT00529451
Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg
Hypertension
P3
Completed1,613RCT, Double-blindAliskiren, Ramipril
NCT00995709
Phase III Study in Refractory Behcet's Disease
Behcet Disease
P3
Completed118RCT, Double-blindAIN457, AIN457, Placebo
NCT01529632
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
P3
Completed193RCT, Double-blindQVA149, NVA237, QAB149, Placebo
NCT00134953
Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
Cognitive Symptoms
P3
Terminated24RCT, Double-blindRivastigmine
NCT03785405
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
Heart Failure
P3
Completed216Open-labelsacubitril/valsartan
NCT00329940
Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Breast Cancer
P3
Completed200Open-labelLetrozole
NCT01103024
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
Uveitis
P3
Withdrawn—RCT, Double-blindAIN457, AIN457, AIN457, Placebo
NCT02091908
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
Influenza, Human
P3
Completed540RCT, Double-blindNovartis Investigational H5N1 vaccine, Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine, Novartis Seasonal Influenza Vaccine
NCT00644059
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
Influenza, Human
P3
Completed4,902RCT, Single-blindAdjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
NCT00365820
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
Constipation
P2P3
Terminated670RCT, Double-blindTegaserod
NCT02962388
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Essential Thrombocythemia
P2P3
Terminated13RCT, Open-labelAnagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα
NCT04935359
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
Metastatic Pancreatic Ductal Adenocarcinoma
P3
Completed511RCT, Double-blindNIS793, Nab-paclitaxel, Gemcitabine, Placebo
NCT00396656
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
Hypertension
P3
Completed30RCT, Open-labelAtenolol, Hydrochlorothiazide (HCTZ)), Valsartan
NCT02474069
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
Moderate to Severe Plaque-type Psoriasis
P3
Completed772RCT, Double-blindSecukinumab
NCT02720536
Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation
Chronic Iron Overload
P3
Completed53Open-labelDeferasirox
NCT01828112
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Non-Small Cell Lung Cancer
P3
Completed231RCT, Open-labelCeritinib, Pemetrexed, Docetaxel
NCT01762761
Eltrombopag Phase III Study In Chinese Chronic ITP Patients
Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
P3
Completed155RCT, Double-blindeltrombopag, placebo
NCT00945841
Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010
Seasonal Influenza
P3
Completed126RCT, Open-labelinactivated split influenza vaccine
NCT03158311
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
Asthma
P3
Completed1,426RCT, Single-blindQVM149, Salmeterol/fluticasone plus tiotropium
NCT02571777
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
Asthma
P3
Completed3,092RCT, Double-blindQVM149 150/50/160, QVM149 150/50/80, QMF149 150/320, QMF149 150/160, salmeterol/fluticasone
NCT00130351
A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma
Asthma
P3
Completed155Open-label—
NCT01448057
Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
Upper Respiratory Tract Infection, Nasal Congestion
P3
Completed341RCT, Single-blindParacetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets, Paracetamol (500 mg) tablets
NCT00802841
Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib
Chronic Myelogenous Leukemia
P3
Completed191RCT, Open-labelnilotinib, imatinib
NCT02292446
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
Polycythemia Vera
P3
Completed161Open-labelRuxolitinib
NCT02116803
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Solid Tumors
P2P3
Completed12Open-labeldovitinib, fulvestrant
NCT00514488
Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)
Chronic Myeloid Leukemia
P3
Completed—RCT, Open-labelSTI571 (400 mg/day; or 800 mg/day)
NCT03626545
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
Non-Small-Cell Lung
P3
Terminated245RCT, Double-blindCanakinumab, Docetaxel
NCT03217422
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
Autoimmune Hepatitis
P2P3
Completed68RCT, Double-blindVAY736
NCT01574651
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
P3
Completed934RCT, Double-blindQVA149, Placebo to tiotropium, Placebo to formoterol, Tiotropium, Formoterol, Placebo to QVA149
NCT00531440
This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.
Renal Transplantation
P3
Completed256RCT, Open-labelEverolimus (RAD001)
NCT01840410
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
Choroidal Neovascularization (CNV)
P3
Completed183RCT, Double-blindRanibizumab
NCT01743989
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
P3
Completed620RCT, Open-labelNilotinib
NCT03259074
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
Ankylosing Spondylitis
P3
Completed859RCT, Single-blindPlacebo, GP2017 (adalimumab biosimilar), AIN457 150 mg
NCT01593527
Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease
Acute Gouty Arthritis
P3
Withdrawn—RCT, Double-blindACZ885, Triamcinelone acetonide
NCT00308425
Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS
De Novo Renal Transplantation
P3
Completed119RCT, Open-labelEnteric-coated Mycophenolate sodium (EC-MPS), valsartan
NCT00376259
Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone
Hepatitis B
P3
Terminated43RCT, Open-labeltelbivudine, adefovir dipivoxil
NCT01160211
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Neoplasms, Breast
P3
Completed369RCT, Open-labelLapatinib, Trastuzumab, Aromatase Inhibitor, Lapatinib
NCT00262990
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Ovarian Cancer, Fallopian Tube Cancer
P3
Completed829RCT, Open-labelEPO906 (Patupilone), doxorubicin
NCT00320710
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Breast Cancer
P3
Completed416RCT, Double-blindZoledronic acid, Placebo
NCT00330317
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
Breast Cancer
P3
Completed300Open-labelletrozole
NCT01410474
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan
Bacterial Meningitis
P3
Completed341Open-labelMeningococcal ACWY conjugate vaccine
NCT01232478
I Change Adherence & Raise Expectations
Cystic Fibrosis
P3
Completed641RCT, Open-label—
NCT04156620
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
Ankylosing Spondylitis
P3
Completed527RCT, Double-blindSecukinumab, Placebo
NCT00241007
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
Hypertension
P3
Completed836RCT, Double-blindVALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE
NCT01727141
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
Chronic Obstructive Pulmonary Disease (COPD)
P3
Completed1,042RCT, Double-blindQVA149, QAB149, NVA237, Placebo
NCT00529529
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
Asthma
P3
Completed805RCT, Double-blindIndacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
NCT00232102
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
Dyspepsia
P3
Completed423Open-labelTegaserod
NCT00667719
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
Essential Hypertension
P3
Completed564Open-labelAliskiren, Amlodipine, Hydrochlorothiazide
NCT00151671
Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
Liver Cancer, Hepatocellular Carcinoma
P2P3
Terminated35RCT, Double-blindOral Impact®, Placebo
NCT01996319
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
Chronic Obstructive Pulmonary Disease
P3
Completed194RCT, Double-blindQVA149, Placebo
NCT00120536
Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
P3
Completed288RCT, Double-blindvildagliptin
NCT00519064
Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases
Influenza Disease
P3
Completed361RCT, Single-blindAdjuvanted influenza vaccine
NCT00136799
Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
Mixed Dyslipidemia, Hypercholesterolemia
P3
Completed325RCT, Double-blindFluvastatin
NCT00579345
Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup
Influenza
P3
Completed1,522RCT, Single-blindCell culture derived seasonal trivalent influenza vaccine (cTIV), Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)., cTIV or eTIV_a, cTIV+PV OR eTIV_a+PV
NCT01202903
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
Persistent Allergic Asthma
P3
Completed616RCT, Double-blindOmalizumab, Placebo
NCT01964989
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Influenza Virus
P3
Completed10,644RCT, Double-blindAdjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
NCT04838613
Study of Diagnostic Performance of [18F]CTT1057 in BCR
Prostatic Neoplasms, Prostate Cancer
P3
Completed190Open-label[18F]CTT1057, [68Ga]Ga-PSMA-11
NCT00231998
Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis
Atopic Dermatitis
P3
Completed240Open-labelPimecrolimus
NCT01161264
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects
Seasonal Influenza
P3
Completed126RCT, Open-labelInfluenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011
NCT00687804
A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
Diabetic Macular Edema
P3
Completed345RCT, Double-blindRanibizumab, Sham to ranibizumab
NCT00413049
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension
Hypertension
P3
Completed698RCT, Double-blindValsartan/amlodipine 80/5 mg, Amlodipine 5 mg
NCT00604500
A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)
Asthma, COPD
P3
Completed272Open-labelSCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
NCT01412944
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
Plaque-type Psoriasis
P3
Completed43RCT, Double-blindsecukinumab 150mg, secukinumab 10mg/kg i.v. regimen
NCT00770081
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
Diabetes Mellitus, Type 2, Renal Insufficiency
P3
Completed75RCT, Double-blindvildagliptin, sitagliptin
NCT01031628
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
Gastrointestinal Stromal Tumors
P3
Terminated5RCT, Open-labelImatinib mesylate, Imatinib mesylate, Imatinib mesylate
NCT01120028
Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
Kidney Transplantation
P2P3
Completed852RCT, Open-labelAlemtuzumab, Basiliximab, Sirolimus, Tacrolimus
NCT00409851
One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension
Hypertension
P3
Completed1,293RCT, Open-labelvalsartan+amlodipine
NCT00845728
Exacerbation Study
Chronic Obstructive Pulmonary Disease
P3
Completed3,439RCT, Double-blindIndacaterol 150 µg, Tiotropium
NCT00806195
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Meningitis, Meningococcal Infection
P3
Completed7,744RCT, Open-labelMenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
NCT03100500
A Long-term Safety Study of QMF149 in Japanese Participants With Asthma
Asthma
P3
Completed51Open-labelQMF149
NCT00332709
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Osteoporosis, Postmenopausal
P3
Completed83RCT, Open-labelLetrozole, Zoledronic acid
NCT00351052
Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis
Atopic Dermatitis
P3
Completed184RCT, Double-blindPimecrolimus, Placebo
NCT00230464
Acute Metabolic Effects of LAF 237 in Type 2 Diabetics
Type 2 Diabetes Mellitus
P3
Completed16RCT, Double-blindLAF 237
NCT00124748
Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)
Leukemia, Myeloid, Chronic Phase
P3
Terminated476RCT, Open-labelImatinib mesylate
NCT00355134
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Multiple Sclerosis
P3
Completed1,083RCT, Double-blindFingolimod, Placebo
NCT03832998
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
Migraine
P3
Completed284RCT, Double-blindErenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
NCT00351832
A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
P3
Completed236RCT, Double-blindVildagliptin
NCT01139021
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
Meningococcal Disease
P3
Completed508Open-labelrMenB+OMV NZ
NCT02598297
Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
Myelofibrosis With High Molecular Risk Mutations
P3
Terminated49RCT, Double-blindRuxolitinib, Ruxolitinib Placebo
NCT01773460
Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane
Metastatic Breast Cancer
P3
Terminated3RCT, Double-blindEverolimus, Everolimus-placebo
NCT02064868
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
Acute Heart Failure (AHF)
P3
Terminated2,666RCT, Open-labelSerelaxin, Standard of Care
NCT01863732
Extension in AS: Sustainability of Benefits, Safety and Tolerability
Spondylitis, Ankylosing
P3
Completed274RCT, Double-blindSecukinumab
NCT00115245
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B
Chronic Hepatitis B
P3
Completed—RCT, Open-labelTelbivudine (LdT), Adefovir Dipivoxil
NCT00739973
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
Hypertension
P3
Completed2,694RCT, Double-blindPlacebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet
NCT01012765
Effect of Indacaterol on Inspiratory Capacity (IC)
Chronic Obstructive Pulmonary Disease
P3
Completed173RCT, Double-blindIndacaterol, Tiotropium, Placebo
NCT04807400
Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents
P3
Completed892RCT, Open-labelInclisiran, Background lipid lowering therapy
NCT00232076
Verification Study of Ciclosporin for Atopic Dermatitis
Severe Atopic Dermatitis
P3
Completed—RCT, Double-blindciclosporin
NCT00973349
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults
Influenza
P2P3
Completed2,719RCT, Single-blindMF59-eH1N1_f
NCT00100555
A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
Osteoporosis
P3
Completed120RCT, Double-blindzoledronic acid
NCT01357252
Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes
Type 2 Diabetes Mellitus
P3
Completed279RCT, Double-blindvildagliptin, Placebo
NCT00391950
Maintaining Bone Strength in Men With Prostate Cancer
Prostate Cancer
P3
Terminated300RCT, Open-labelZoledronic acid
NCT01870778
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
Acute Heart Failure
P3
Completed6,600RCT, Double-blindRLX030, Placebo
NCT01033747
Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study
Liver Iron Overload
P2P3
Completed70Open-labelDeferasirox, Deferasirox
NCT00975715
Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures
Partial Onset Seizures
P2P3
Completed99RCT, Double-blindTRI476, Placebo to TRI476, Benzodiazepines
NCT01680016
A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults
Rabies
P3
Completed644RCT, Open-labelZagreb, Essen
NCT00329849
Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age
Meningococcal Disease
P3
Completed1,500RCT, Single-blindMeningococcal ACWY-CRM conjugate vaccine, Meningococcal ACWY-PS polysaccharide vaccine
NCT00239876
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
Renal Transplantation
P3
Completed140RCT, Open-labelFTY720
NCT02201290
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Purpura, Thrombocytopenic, Idiopathic
P3
Completed9Open-labelEltrombopag Tablets, Eltrombopag PfOS
NCT00003884
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
Hypercalcemia of Malignancy, Lung Cancer
P3
Completed600RCTzoledronic acid
NCT00171418
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
Gastroesophageal Reflux Disease (GERD)
P3
Completed54RCT, Open-labelTegaserod
NCT01171976
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
Diabetic Macular Edema
P3
Completed373RCT, Single-blindRanibizumab
NCT00267189
RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency
Liver Transplantation
P3
Completed145RCT, Open-labelEverolimus, Calcineurin inhibitors (CNI), Mycophenolate acid (MPA)/ Azathioprine (AZA), Steroids
NCT00242580
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
Macular Degeneration, Choroidal Neovascularization
P3
Completed111RCT, Double-blindVerteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
NCT02792218
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
P3
Completed930RCT, Double-blindOfatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
NCT00658320
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
Kidney Transplantation
P3
Completed122RCT, Open-labelEverolimus, Mycophenolate mofetil (MMF), Basiliximab, Cyclosporine A, Corticosteroid
NCT01093846
38 Week Extension Study to CAIN457C2303
Uveitis
P3
Terminated59RCT, Double-blindAIN457, AIN457, Placebo AIN457
NCT00856297
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
Meningococcal Meningitis
P3
Completed389Open-labelMenACWY-CRM conjugate vaccine, Licensed comparator
NCT01572727
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Breast Cancer
P2P3
Completed416RCT, Double-blindPaclitaxel, BKM120 matching placebo, BKM120
NCT00235391
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
Thalassemia, Sickle Cell Disease
P3
Completed1,683Open-labelDeferasirox
NCT00413829
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
Age Related Macular Degeneration
P2
Completed20Open-labelIntravitreal ranibizumab with photodynamic therapy
NCT01393340
Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma
Nasal Polyposis, Asthma
P2
Completed23RCT, Double-blindOmalizumab, Placebo
NCT00784446
First-line Therapy of Stage IV Colorectal Cancer
Stage IV Colorectal Cancer
P1P2
Completed51Open-labelOxaliplatin, Capecitabine, Bevacizumab, Imatinib
NCT00719264
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Carcinoma, Adenocarcinoma
P2
Completed365RCT, Open-labelRAD001(everolimus), interferon alfa-2a, bevacizumab
NCT02404844
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer
Breast Cancer
P2
Completed48Open-labelBKM120, Tamoxifen
NCT01520103
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer
P2
Completed139RCT, Open-labelVinorebine, Everolimus, Vinorelbine
NCT01163227
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
Schizophrenia Disorders
P2
Completed57RCT, Double-blindPlacebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
NCT02608268
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Advanced Malignancies
P1P2
Terminated252Open-labelMBG453, PDR001, Decitabine
NCT07923773
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
P2
Not Yet Recruiting88Open-labelDDY391
NCT01064791
Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients
Renal Transplantation
P2
Completed298RCT, Double-blindsotrastaurin (Dose 1) + tacrolimus + standard of care medications, sotrastaurin (Dose 2) + tacrolimus + standard of care medications, sotrastaurin (Dose 3) + tacrolimus + standard of care medications, mycophenolic acid + tacrolimus + standard of care medications
NCT01013597
Trial of LBH589 in Metastatic Thyroid Cancer
Thyroid Carcinoma
P2
Completed13Open-labelLBH589
NCT00930982
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
Bronchiectasis
P2
Completed124RCT, Double-blindCiprofloxacin (Cipro, BAYQ3939), Placebo
NCT03988608
Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.
Aplastic Anemia
P2
Completed20Open-labelEltrombopag
NCT00557440
Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma
Asthma
P2
Completed37RCT, Double-blindfluticasone propionate/salmeterol, indacaterol maleate / mometasone furoate, placebo to indacaterol/mometasone, placebo to fluticasone propionate/salmeterol
NCT00537524
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
Prophylaxis of Avian Influenza
P2
Completed471RCT, Single-blindH5N1 Influenza Vaccine, H5N1 Influenza Vaccine
NCT04812483
Immunomodulation With Eltrombopag in ITP
Primary Immune Thrombocytopenia (ITP)
P2
Completed2RCT, Open-labelEltrombopag (Revolade®), standard therapy (without eltrombopag): HD-DXM
NCT00788775
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Mucosal Lentiginous Melanoma, Acral Melanoma
P2
Completed20Open-labelNilotinib
NCT00216112
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Ovarian Cancer
P2
Completed23Open-labelImatinib Mesylate, Docetaxel
NCT00411619
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
P1P2
Completed28Open-labelEverolimus
NCT00987545
Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence
Keloids
P2
Terminated3RCT, Double-blindQAX576, QAX576 placebo
NCT00743288
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
Multiple Myeloma
P1P2
Completed40Open-labelMelphalan, Panobinostat
NCT01528501
Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)
Metastatic Gastric Cancer
P2
Terminated28Open-labelPanobinostat (LBH589)
NCT00303251
Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
Melanoma
P1P2
Completed47Open-labelTKI258
NCT02300545
Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Sarcoma, Soft Tissue, Soft Tissue Sarcoma
P2
Completed56Open-labelPazopanib
NCT01703169
Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
Severe Aplastic Anemia, Very Severe Aplastic Anemia
P2
Completed13Open-labelEltrombopag
NCT04795466
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
Mild Cognitive Impairment, Alzheimer Disease
P2
Terminated34RCT, Double-blindCanakinumab
NCT02160041
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Solid Tumor, Hematologic Malignancies
P2
Terminated84Open-labelBGJ398
NCT01028222
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Melanoma
P2
Completed55Open-labelNilotinib, DTIC
NCT03387475
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
Myelodysplasia
P2
Completed39Open-labelDeferasirox
NCT00171951
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Cushing Disease
P2
Completed19Open-labelPasireotide
NCT00582556
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
Prostate Cancer
P2
Completed44RCT, Open-labelZometa, zometa, Zometa
NCT00987870
Safety and Efficacy of BFH772 in Psoriasis Patients
Psoriasis, Arthritis
P1P2
Completed15RCT, Double-blindBFH772, Placebo, BFH772, Placebo, calcipotriol/betamethasone
NCT01660295
Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects
Renal Insufficiency
P1P2
Completed32Open-labelCertoparin 3,000 IU Once Daily, Certoparin 3,000 IU Twice a Day, Certoparin 8,000 IU Once Daily, Certoparin 8,000 IU Twice a Day
NCT00827567
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
Breast Cancer
P2
Terminated6Open-labelRAD 001
NCT01207492
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor
P2
Completed17Open-labelnilotinib
NCT02270944
Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine
Infections, Streptococcal, Streptococcal Infections
P2
Completed1,053RCT, Double-blindGBS Vaccine, GBS Vaccine
NCT02588339
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
Graft Versus Host Disease, GVHD
P2
Completed42Open-labelPanobinostat, Sirolimus, Tacrolimus
NCT01072175
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
Cancer
P2
Completed430Open-labelGSK2118436, GSK1120212
NCT02342600
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
Gastrointestinal Stromal Tumors
P2
Withdrawn—Open-labelPazopanib, Trametinib
NCT00247650
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
Breast Cancer
P2
Completed190RCT, Open-labelZoledronic Acid; Letrozole
NCT01423110
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Sporadic Inclusion Body Myositis
P2
Completed14RCT, Double-blindBYM338, Placebo
NCT01446289
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
Streptococcal Infection, Gram-positive Bacterial Infection
P2
Completed86RCT, Single-blindGroup B Streptococcus Trivalent Vaccine, Placebo
NCT01802879
Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator
Hematologic Neoplasms
P2
Completed9Open-labelPanobinostat
NCT01480791
Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries
Hypertension, Diabetes
P2
Withdrawn—RCT, Double-blindAliskiren vs. hydrochlorothiazide, Hydrochlorothiazide
NCT00461773
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Hormone-Sensitive Breast Cancer, Breast Cancer
P2
Terminated5RCT, Open-labelLetrozole, Bevacizumab
NCT01271920
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
Advanced HER2-positive Breast Cancer
P1P2
Completed45Open-labelAUY922, Trastuzumab
NCT03610724
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
Non-Hodgkin Lymphoma
P2
Completed34Open-labelTisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
NCT00140803
Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration
Age-Related Macular Degeneration
P2
Completed106RCT, Single-blindVisudyne, Kenalog
NCT00649883
Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months
Influenza
P2
Completed360RCT, Single-blindInfluenza Trivalent Inactivated vaccines Novartis, Influenza Trivalent Inactivated vaccines
NCT00704483
Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
P2
Completed321RCT, Open-labelSBR759, Sevelamer HCl, SBR759, Sevelamer HCl
NCT02927366
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
Pulmonary Arterial Hypertension
P2
Terminated8RCT, Double-blindQCC374, Placebo Matching
NCT00912340
Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
Breast Cancer
P2
Completed70RCT, Open-labelEverolimus, Trastuzumab
NCT01958112
GSK1120212+GSK2141795 for Cervical Cancer
Cervical Cancer
P2
Terminated14Open-labelGSK1120212 (trametinib), GSK2141795
NCT03944707
Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients
Asthma
P2
Terminated76RCT, Double-blindLOU064 100 mg, Placebo
NCT06362759
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
Chronic Kidney Diseases, Chronic Kidney Insufficiency
P2
Completed143RCT, Double-blindTOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG
NCT02294786
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Cancer
P2
Terminated62RCT, Open-labelLapatinib, Capecitabine, Octreotide
NCT01529554
Controlled Level EVERolimus in Acute Coronary Syndromes
Acute Coronary Syndromes
P1P2
Completed150RCT, Double-blindEverolimus, Placebo
NCT01528345
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Metastatic Breast Cancer
P2
Terminated97RCT, Double-blindDovitinib, Fulvestrant, Dovitinib Placebo
NCT00447694
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
Beta-thalassemia, Iron Overload
P2
Completed30Open-labelDeferasirox
NCT04391894
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
Dry Eye
P2
Completed718RCT, Double-blindECF843
NCT01524341
Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
Malaria
P2
Completed27Open-labelKAE609
NCT01024946
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Malignant Pleural Mesothelioma
P2
Completed11Open-labeleverolimus
NCT02290431
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Relapse/Refractory Multiple Myeloma
P2
Completed31Open-labelLBH589 (panobinostat), bortezomib, dexamethasone
NCT04566445
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
Dry Age-related Macular Degeneration
P2
Terminated255RCT, Double-blindGT005
NCT01163929
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
Breast Cancer
P2
Withdrawn—RCT, Open-labelpaclitaxel
NCT00781261
Osteonecrosis of the Hip and Bisphosphonate Treatment
Osteonecrosis
P2
Unknown120RCT, Double-blindZoledronic Acid, Placebo
NCT01194908
Re-expression of ER in Triple Negative Breast Cancers
Breast Cancer, Breast Tumors
P1P2
Terminated5Open-labelDecitabine, LBH589, Tamoxifen
NCT01438996
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
Typhoid Fever
P2
Completed51Open-labelNVGH Vi-CRM197
NCT01596062
Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)
Renal Transplantation
P2
Completed16RCT, Open-labelSimulect®, Neoral®, Certican®, Myfortic®, Corticosteroids
NCT02920892
AFQ056 for Language Learning in Children With FXS
Fragile X Syndrome
P2
Completed110RCT, Double-blindAFQ056, Placebo
NCT00381615
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Healthy
P2
Completed147RCT, Open-labelrMenB, rMenB+OMV, DTaP-Hib-IPV, PC7, MenC-CRM, MenC-Hib, MMR
NCT04139317
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
Non-small Cell Lung Cancer (NSCLC)
P2
Terminated76RCT, Open-labelCapmatinib, Pembrolizumab
NCT01349660
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Glioblastoma Multiforme
P1P2
Completed88Open-labelBevacizumab, BKM120
NCT01140568
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
Glioma
P2
Completed38Open-labelnilotinib
NCT01449591
Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients
Erythemato-telangiectatic Rosacea
P2
Completed36RCT, Double-blindBFH772 1% ointment, Vehicle ointment, Noritate® 1% cream
NCT04868968
Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
Familial Cold Autoinflammatory Syndrome
P2
Completed4Open-labelDFV890
NCT06881823
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
Prostate Cancer
P1P2
Withdrawn—RCT, Open-labelAAA602, AAA802, Gallium (68Ga) gozetotide, Piflufolastat (18F), Flotufolastat F 18, 18F-PSMA-1007
NCT00172068
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Primary Breast Cancer
P2
Terminated96RCT, Open-labelZoledronic acid + Calcium/Vitamin D
NCT06155994
68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours
Neuroendocrine Tumors
P1P2
Completed12Open-label68Ga-DOTA-MGS5
NCT01327053
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Basal Cell Carcinoma
P2
Completed230RCT, Double-blindLDE225
NCT00072709
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
P2
Completed551RCT, Double-blindTCH346
NCT00732771
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
Primary Hyperaldosteronism
P2
Completed12Single-blindLCI699
NCT03280030
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
Acute Myeloid Leukemia
P2
Completed67RCT, Double-blindMidostaurin, Placebo
NCT00709761
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
Neoplasms, Breast
P2
Completed60Open-labelLapatinib/nab-Paclitaxel
NCT02145715
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
Multiple Myeloma
P1P2
Unknown54Open-labelVelcade, Thalidomide, Dexamethasone, Panobinostat
NCT04410523
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
Asthma
P2
Terminated335RCT, Double-blindCSJ117, Placebo
NCT00748813
Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009
Seasonal Influenza
P2
Completed133Open-labelInfluenza Vaccine, Formulation 2008-2009
NCT02460224
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Advanced Solid Tumors
P1P2
Completed490Open-labelLAG525, PDR001
NCT00885196
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
Moderate and Severe Plaque Psoriasis
P2
Completed336RCT, Double-blindPlacebo, AEB071
NCT00457964
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
Tuberous Sclerosis, Lymphangioleiomyomatosis
P1P2
Completed36Open-labelRAD001
NCT01546532
Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
Chronic Heart Failure (CHF)
P2
Completed118RCT, Double-blindRLX030, Placebo
NCT04905316
A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer
Non-small Cell Lung Cancer
P2
Completed41Open-labelCanakinumab, Durvalumab, Chemotherapy
NCT00136409
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Myelofibrosis, Myeloid Metaplasia
P2
Completed34Open-labelImatinib mesylate
NCT00942734
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
Head And Neck Cancer
P2
Completed49Open-labelErlotinib, RAD001
NCT04191421
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
P1P2
Completed35Open-labelSiltuximab, Spartalizumab
NCT02038816
Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes
P2
Terminated1RCT, Open-labelDeferasirox + Azacitidine, Azacitidine
NCT00639392
Phase 1 Study of Zoledronic Acid in Sickle Cell Disease
Sickle Cell Disease
P1P2
Withdrawn—RCT, Double-blindPlacebo, Zoledronic Acid
NCT02891395
Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host
Graft Versus Host Disease
P2
Completed65Open-labelImatinib Mesylate and Nilotinib
NCT00746330
Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma
Asthma
P2
Completed32RCT, Double-blindMometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
NCT02379637
Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough
Common Cold Associated With Cough
P2
Completed70RCT, Double-blindN-acetylcysteine, Placebo
NCT01491672
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
P2
Completed134Open-labelRAD001
NCT00138632
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
Wet Age-Related Macular Degeneration
P1P2
Completed50RCT, Double-blindPTK787, PTK787, Placebo
NCT01610336
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Non-small Cell Lung Cancer
P2
Completed161Open-labelINC280, Gefitinib
NCT02398500
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
Age-related Macular Degeneration (AMD)
P1P2
Terminated25RCT, Double-blindLMG324, Ranibizumab 0.5 mg, Sham
NCT04323436
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
Carcinoma, Non-Small-Cell Lung
P2
Terminated31RCT, Double-blindSpartalizumab, Capmatinib, spartalizumab placebo
NCT02531932
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
Breast Cancer
P2
Completed64RCT, Open-labelCarboplatin, Everolimus
NCT01132664
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
Metastatic Breast Cancer, HER2+ Breast Cancer
P1P2
Terminated72Open-labelBKM120, Trastuzumab, Capecitabine
NCT00171249
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
P2
Completed293Open-labelSTI571 400 mg, STI571 600 mg
NCT00501852
Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium
Chronic Obstructive Pulmonary Disease
P2
Completed83RCT, Double-blindNVA237, Placebo, Tiotropium
NCT04437368
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
Dry Age-related Macular Degeneration
P2
Terminated98RCT, Double-blindGT005
NCT02002689
LDE225 for Patients With PTCH1 or SMO Mutated Tumors
PTCH1 or SMO Activated Solid and Hematologic Tumors
P2
Terminated10Open-labelLDE225
NCT02291913
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Breast Cancer
P2
Completed48Open-labelEverolimus, Exemestane, Tamoxifen, Fulvestrant, Anastrozole, Letrozole, Toremifine
NCT01116440
A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis
Pelvic Pain Associated With Refractory Endometriosis
P2
Terminated27RCT, Double-blindBGS649, Placebo
NCT02750215
A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Malignant Non-small Cell Neoplasm of Lung Stage IV
P2
Completed20Open-labelCapmatinib (INC280)
NCT03664518
to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection
Thrombocytopenia Purpura, Chronic HBV Infection
P2
Completed48Open-labelEltrombopag
NCT04035668
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
Sjögren Syndrome
P2
Terminated73RCT, Double-blindRemibrutinib, Placebo
NCT00316615
Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.
Influenza Disease
P2
Completed100Open-labelinfluenza vaccine
NCT00291135
Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
P2
Completed42Open-labelletrozole
NCT01964235
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
P2
Withdrawn—RCT, Double-blindINC280, Placebo
NCT00481676
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Chronic Urticaria
P2
Completed49RCT, Double-blindOmalizumab 75-375 mg, Placebo to omalizumab, Loratadine, Clemastine
NCT03499899
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
Triple-negative Breast Cancer
P2
Completed88RCT, Open-labelLAG525, PDR001, Carboplatin
NCT01167335
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
Partial Onset Seizures
P2
Withdrawn—RCT, Double-blindBGG492, Placebo
NCT00230074
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)
Amyotrophic Lateral Sclerosis
P2
Completed350RCT, Double-blindTCH346
NCT03781414
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
Liver Transplant Rejection
P2
Terminated129RCT, Open-labelCFZ533, Tacrolimus - MMF - corticosteroids
NCT00276926
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia (CEL)
P2
Unknown—Open-labelSTI571
NCT01676714
Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
Non-Small Cell Lung Cancer, Colorectal Cancer
P2
Completed10Open-labelDovitinib
NCT02086552
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
P2
Completed28Open-labelLenalidomide, Sonidegib
NCT01336634
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Cancer
P2
Completed177Open-labelDabrafenib, Trametinib
NCT00448149
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
Carcinoma, Renal Cell
P1P2
Completed55Open-labelRAD001, Sorafenib
NCT01109940
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis
Ankylosing Spondylitis
P2
Completed39Open-labelAIN457A
NCT01365468
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
P2
Terminated9Open-labelEverolimus (RAD001)
NCT01628913
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumors (pNET)
P2
Terminated62RCT, Open-labelBEZ235, Everolimus
NCT02000882
STAR Cape+BKM120 MBC With Brain Met
Brain Metastases, Breast Cancer
P2
Completed10Open-labelBKM120, capecitabine, Trastuzumab
NCT00451035
Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase
Chronic Myeloid Leukemia in Chronic Phase
P2
Terminated29Open-labelLBH589
NCT01911546
Role of Everolimus in Highly Sensitized Patients
Highly-sensitized Kidney Transplant Recipients
P2
Completed20Open-labeleverolimus + low-dose tacrolimus
NCT05124925
Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.
Sjogren Syndrome
P2
Completed21Open-labelIanalumab
NCT03517540
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
Non-alcoholic Steatohepatitis (NASH)
P2
Completed193RCT, Double-blindTropifexor (LJN452), Cenicriviroc (CVC)
NCT01390350
Ilaris® Effects in Schnitzler Syndrome (ILESCH)
Schnitzler Syndrome
P2
Completed20RCT, Double-blindCanakinumab, Placebo
NCT01148797
Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)
Colchicine Resistant/Intolerant Familial Mediterranean Fever
P2
Completed15Open-labelCanakinumab
NCT01452113
Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy
Diabetes Mellitus
P2
Completed21Open-labelVildagliptin
NCT03765788
A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
Giant Cell Arteritis
P2
Completed52RCT, Double-blindSecukinumab 300 mg, s.c., Prednisolone, Placebo
NCT04161118
TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Non Hodgkin Lymphoma
P2
Terminated3Open-labelCTL019
NCT01279473
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
P1P2
Completed42Open-labelNilotinib
NCT00116376
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme
P1P2
Completed64Open-labelAEE788
NCT01948817
Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses
Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
P2
Withdrawn—Open-labelDeferasirox
NCT00768040
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
Diabetic Macular Edema
P2
Terminated39RCT, Double-blindAliskiren, Placebo
NCT00342940
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
Influenza
P2
Withdrawn—Open-labelinfluenza surface antigen inactivated vaccine
NCT02017860
Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Neoplasms
P2
Completed4Open-labelEverolimus
NCT01254227
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
Cardiac Iron Overload
P2
Completed60Open-labelDeferasirox and Deferoxamine
NCT01294579
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Lymphoma, Non-Hodgkin
P2
Completed49Open-labelOfatumumab, Bendamustine
NCT01090973
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
Non-Hodgkin's Lymphoma
P2
Terminated1Open-labelLBH589
NCT03100058
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
Obesity, Overweight
P2
Completed460RCT, Double-blindLIK066, Placebo
NCT06430671
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
Relapsing-remitting Multiple Sclerosis (RRMS)
P1
Completed11Open-labelCLS12311 low, CLS12311 medium, CLS12311 high, uncoupled RBCs
NCT00969046
Dose-Escalation Study in Advanced Colon Cancer Patients
Colon Cancer
P1
Completed60RCT, Open-labelEPO906 (patupilone)
NCT05330273
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
Malaria
P1
Completed14Open-labelGanaplacide, Efavirenz
NCT02227940
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
Advanced Malignant Solid Neoplasm, ALK Positive
P1
Completed38Open-labelCeritinib, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation
NCT00703703
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Healthy
P1
Completed117RCT, Double-blindDarifenacin, Tolterodine, Placebo
NCT02997969
Safety and Immune Response to a Clade C DNA HIV Vaccine
HIV Infections
P1
Completed132RCT, Double-blindDNA-HIV-PT123 vaccine, Protein/MF59 vaccine, Placebo
NCT00942682
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Neuroendocrine Tumor, Carcinoid Tumor
P1
Completed21Open-labelSorafenib, RAD001
NCT03434262
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Anaplastic Astrocytoma, Anaplastic Ependymoma
P1
Completed68Open-labelGemcitabine, ribociclib, sonidegib, trametinib, filgrastim
NCT00442741
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)
Solid Tumors
P1
Withdrawn—Open-labelPatupilone, Patupilone + Omeprazole
NCT02182622
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Prostate Cancer
P1
Withdrawn—Open-labelDocetaxel, Prednisone, LDE225
NCT00967928
Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer
Cervical Cancer
P1
Withdrawn—Open-labelRAD001, Cisplatin
NCT03574545
Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
P1
Completed48RCT, Open-labelianalumab
NCT00535951
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Carcinoma, Non-Small-Cell Lung, Mesothelioma
P1
Completed18Open-labelLBH589
NCT02078609
A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
AML and High Risk MDS
P1
Completed70Open-labelLGH447, LGH447 + midostaurin
NCT04330664
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Advanced Cancer, Metastatic Cancer
P1
Completed86Open-labelMRTX849, TNO155
NCT03114319
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
P1
Terminated227Open-labelTNO155, TNO155 in combination with EGF816 (nazartinib)
NCT03876028
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Diffuse Large B-cell Lymphoma
P1
Terminated10Open-labelTisagenlecleucel, Ibrutinib
NCT01469572
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Neuroendocrine Tumors
P1
Completed13Open-labelPasireotide, Everolimus
NCT02422589
A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors
ALK-positive Advanced Tumors
P1
Completed33Open-labelceritinib, warfarin, midazolam
NCT02974725
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Non-Small Cell Lung Cancer, Melanoma
P1
Terminated241Open-labelLXH254, LTT462, Trametinib, Ribociclib
NCT05472220
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
Solid Tumors, Adult, PIK3CA Mutation-Related Tumors
P1
Withdrawn—Open-labelAlpelisib, Carboplatin, Hyperpolarized Carbon-13 (13C) Pyruvate
NCT04612062
A First-in-Human Study of CEE321 in Adult Subjects
Atopic Dermatitis
P1
Completed28Open-labelCEE321
NCT00503360
Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension
Ocular Hypertension
P1
Completed80RCT, Double-blindSAD448
NCT02240719
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
P1
Completed20Open-labeleverolimus, bendamustine hydrochloride
NCT03696771
Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer
NON-breast HER2+ Malignancies
P1
Completed18Open-labelNJH395
NCT01429337
PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Hepatic Impairment
P1
Completed43Open-labelMidostaurin, Midostaurin
NCT02323139
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
MDS
P1
Completed23Open-labelAzacitidine and LDE255
NCT01285466
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Metastatic or Locally Advanced Solid Tumors
P1
Completed110Open-labelBEZ235 + paclitaxel, BKM120 + paclitaxel, BEZ235 + paclitaxel + trastuzumab, BKM120 + paclitaxel + trastuzumab
NCT01898845
A Phase I Study of LEE011 in Asian Patients
Advanced Solid Tumors
P1
Completed17Open-labelLEE011
NCT01820325
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
Non-Small Cell Lunch Cancer
P1
Terminated6RCT, Double-blindBuparlisib, Buparlisib placebo, Carboplatin, Paclitaxel
NCT00006368
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Brain and Central Nervous System Tumors, Breast Cancer
P1
Completed60——
NCT06130540
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Giant Cell Arteritis, Polymyalgia Rheumatica
P1
Completed65RCT, Open-labelSecukinumab
NCT07908680
A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia
Schizophrenia
P1
Not Yet Recruiting36RCT, Double-blindXEP527, Placebo
NCT02491281
First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement
Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
P1
Completed28RCT, Double-blindLNA043, Placebo
NCT01727128
Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment
Hepatic Impairment
P1
Completed31Open-labelBKM120
NCT02900664
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
P1
Completed283Open-labelPDR001, ACZ885, CJM112, TMT212, EGF816
NCT02586675
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
Breast Cancer, Breast Cancer - Female
P1
Completed7Open-labelTamoxifen, Ribociclib, Goserelin
NCT00613665
Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults
Helicobacter Pylori, Gastritis
P1
Completed113RCT, Single-blindhelicobacter pylori vaccine, helicobacter pylori vaccine, helicobacter pylori vaccine, helicobacter pylori vaccine, Placebo, helicobacter pylori vaccine, helicobacter pylori vaccine
NCT02167854
Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Breast Cancer
P1
Completed23Open-labelBYL719, LJM716, TRASTUZUMAB
NCT01290380
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
Solid Tumor Malignancies
P1
Terminated54RCT, Open-labelASA404, DMXAA, DXAA
NCT01428297
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
Healthy Volunteers, Atopic Dermatitis
P1
Completed12RCT, Double-blindBPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, Placebo (Vehicle), BPR277, Placebo (Vehicle)
NCT02282371
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
Head and Neck Squamous Cell Cancer
P1
Completed16Open-labelCetuximab, BYL719
NCT04635800
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
Macular Edema, Diabetic Macular Edema
P1
Completed21Open-labelMHU650
NCT02048787
Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.
Renal Impairment
P1
Completed19Open-labelBuparlisib
NCT02614508
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
P1
Terminated1Open-labelBuparlisib, Ibrutinib, Ofatumumab
NCT00426140
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
Advanced Malignancies, Solid Tumors
P1
Completed5Open-labelPatupilone
NCT01064089
Dose Escalation of HSP990 in Japan/Korea
Advanced Solid Tumors
P1
Terminated17Open-labelHSP990
NCT04315233
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
P1
Terminated12Open-labelRibociclib, Belinostat
NCT01632358
Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients
Dyslipidaemia
P1
Completed279Double-blindTAP311 capsules, Placebo
NCT00414947
Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers
Healthy
P1
Completed30RCT, Open-labelVildagliptin (LAF237)
NCT02678260
Phase I Study of PDR001 in Patients With Advanced Malignancies.
Advanced Malignancies
P1
Completed18Open-labelPDR001
NCT00613132
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Glioblastoma, Gliosarcoma
P1
Completed78Open-labelGleevec, RAD001, and Hydroxyurea
NCT01854606
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
P1
Completed31Open-labelAEB071, Everolimus
NCT00420615
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies
Solid Tumors
P1
Completed34RCT, Open-labelPatupilone and Omeprazole, Patupilone + Midalzolam
NCT01613976
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
P1
Completed10Open-labelPanobinostat
NCT00570284
A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
Cancer
P1
Completed36Open-labelLBH589
NCT02375958
PCA062 in pCAD-positive Tumors.
Triple Negative Breast Cancer, Head & Neck Cancer
P1
Completed47Open-labelPCA062
NCT00586443
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
Solid Tumors
P1
Completed56Open-labelbevacizumab, everolimus, panitumumab
NCT00724776
Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients
Chronic Hepatitis C
P1
Completed30Open-labelAlbinterferon alfa 2b
NCT01875523
PK of Serelaxin in Severe Renal Impairment and ESRD
Renal Failure, Chronic, End-Stage Renal Disease
P1
Completed36Open-labelSerelaxin
NCT00849550
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.
Unspecified Adult Solid Tumor, Protocol Specific, Cancer
P1
Completed32Open-labelcapecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)
NCT01336842
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
Solid Tumors, Non-Small Cell Lung Cancer (NSCLC)
P1
Completed23Open-labelPanobinostat, Cisplatin, Pemetrexed
NCT02032810
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
Melanoma, Skin Cancer
P1
Completed17Open-labelPanobinostat, Ipilimumab
NCT03834922
Providing Standardized Consented PROMs (Patient Reported Outcome Measures) for Improving Pain Treatment
Pain, Postoperative
Completed3,322——
NCT05575843
Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®
Multiple Sclerosis (MS)
N/A
Completed101RCT, Single-blind—
NCT00150891
Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection
Renal Failure, Chronic
Completed84—cyclosporine A, tacrolimus, azathioprine, mycophenolate mofetil
NCT05677542
Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study
Axial Spondyloarthritis, Psoriatic Arthritis
Completed758—secukinumab
NCT01490983
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia
N/A
Terminated14RCT, Open-label—
NCT05407740
"Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease"Disease
Change in Albumin to Creatinine Ratio and Glomerular Filtration Rate, Progression of Kidney Failure and or All-cause Mortality
Completed355——
NCT01098786
Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine
Swine-Origin Influenza A H1N1 Virus
Completed556—Cell-derived A/H1N1 influenza HA vaccine
NCT05834673
VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN)
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Heart Disease (CHD)
N/A
Terminated6RCT, Open-label—
NCT05021419
Efficacy of a Streamlined Heart Failure Optimization Protocol
Heart Failure with Reduced Ejection Fraction, Chronic Heart Failure
N/A
Completed60RCT, Open-label—
NCT00424801
Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris
Microvascular Angina, Hypertension
N/A
Terminated10Open-labelLercanidipine, Valsartan, Nicorandil, Doxazosin, Moxonidin, Pindolol, Amiloride, hydrochlorothiazide
NCT05073120
Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib
Breast Cancer
Completed103——
NCT05294289
Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study
PIK3CA-related Overgrowth Spectrum
Completed77——
NCT02551224
Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive (COPD)
N/A
Completed100RCT, Open-label—
NCT01285479
The Gilenya Pregnancy Registry
Multiple Sclerosis
Completed312—Fingolimod
NCT01592097
Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS
Multiple Sclerosis
Completed51——
NCT07770074
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
Radioiodine-refractory Differentiated Thyroid Cancer
Not Yet Recruiting200——
NCT01442194
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Multiple Sclerosis
Completed3,076—other disease-modifying therapy, Fingolimod
NCT02194803
Observation of Treatment Patterns With Lucentis in Approved Indications
Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
Completed5,778——
NCT01380288
Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine
Alzheimer's Disease
N/A
Completed300Open-labelrivastigmine patch
NCT01542866
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
Age Related Macular Degeneration (AMD)
N/A
Completed160Open-label—
NCT00203671
Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation
Kidney Diseases
Completed651——
NCT00149981
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
Organ Transplantation
NO_LONGER_AVAILABLE——everolimus (RAD)
NCT04028245
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
Carcinoma, Renal Cell
Early P1
Completed17Open-labelSpartalizumab, Canakinumab
NCT05787236
A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
Moderate-to-severe Plaque Psoriasis
Completed79——
NCT07168694
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
Secondary Progressive Multiple Sclerosis
Completed606——
NCT04498871
MAP to Provide Access to Nilotinib, for Patients With HES
Hypereosinophilic Syndrome (HES)
NO_LONGER_AVAILABLE——Nilotinib
NCT05853445
A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera
Polycythemia Vera
Completed467——
NCT04614831
A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis
Plaque Psoriasis, Psoriatic Arthritis
Completed4,978——
NCT02637219
Innate Immune Response in COPD
Pulmonary Disease, Chronic Obstructive, Immunity, Innate
Completed30——
NCT02044237
Online Treatment of Trichotillomania
Trichotillomania, Alexithymia
N/A
Completed105RCT, Double-blind—
NCT05112835
Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice
Neovascular Age-related Macular Degeneration
Terminated302——
NCT04645589
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis
Lupus Nephritis
Completed69—Myfortic
NCT06760624
Effectiveness of Ofatumumab in Real-world Practice
Multiple Sclerosis
Completed779——
NCT03413722
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus
End Stage Renal Disease
Completed30—Tacrolimus, Everolimus
NCT03749681
Neuroendocrine Tumors of Old Patients in the West of France
Neuroendocrine Tumors
Unknown306——
NCT05622929
Cluster Randomized Trial of a Digital Quality Improvement Intervention on LDLCholesterol Control
Cardiovascular Diseases, Atherosclerosis
N/A
Completed1,465RCT, Open-label—
NCT05848219
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib
Metastatic Melanoma
Terminated543——
NCT00361595
Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
Osteoporosis
N/A
Completed35Open-labelzoledronic acid
NCT00749320
Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
N/A
Completed32Open-label—
NCT07450170
A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China
Chronic Urticaria
Completed3,485——
NCT02232503
Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia
Diabetic Retinopathy, Diabetic Macular Edema
Completed4,011——
NCT01733082
The Mycophenolate Pregnancy Registry
Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
Completed400——
NCT05266469
Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf
Relapsing Multiple Sclerosis
Completed168——
NCT02264665
OPALINE : A Study Of Morbidity And Mortality At 2 Years
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
Completed144—sunitinib, everolimus, chemotherapies recommended in france
NCT05334472
A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis
Multiple Sclerosis
Completed105——
NCT05388916
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
Moderate to Severe Chronic Plaque Psoriasis
Completed42——
NCT02671006
Monitoring Chronic Urticaria Basophil Irritability by Cytometry
Urticaria
Completed60——
NCT01220115
A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients
Sickle Cell Disease
Completed498——
NCT04935411
Russian Registry of Patients With nAMD
Neovascular Age-Related Macular Degeneration
Terminated2,665——
NCT01936519
Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.
Immunosuppression, Renal Failure
N/A
Completed24RCT, Open-labelArm A: Everolimus, Calcineurin Inhibitor
NCT01416311
Drug Use Investigation for REVOLADE (ITP)
Purpura, Thrombocytopaenic, Idiopathic
Completed5,797—Eltrombopag
NCT07376265
A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
Heart Failure
Completed1,249——
NCT00513487
Effects of Multiple Nasal Exposures to House Dust Mite Allergen on Nasal and Body Inflammation and Airway Sensitivity
Allergic Rhinitis
N/A
Completed18RCT, Open-labelDust mite extract, Fluticasone, Methacholine
NCT07681258
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
Chronic Myeloid Leukemia
Not Yet Recruiting80——
NCT01694589
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Resectable Pancreatic Cancer
Early P1
Withdrawn—Open-labelLDE-225
NCT05082415
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
Age-related Macular Degeneration (AMD)
Completed9,456—Brolucizumab
NCT01163240
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
Liver Diseases, Hepatitis, Chronic
Completed1,640——
NCT07072013
An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer
Breast Cancer
Completed1,937——
NCT01376115
Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
Cancer
Completed343—Nelarabine
NCT05426980
Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study
Multiple Sclerosis, Multiple Sclerosis Lesion
Completed654——
NCT00892398
Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab
Glaucoma
N/A
Completed242RCT, Single-blindranibizumab
NCT07566988
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
Multiple Sclerosis
Completed2,604——
NCT07465679
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
Heart Failure With Reduced Ejection Fraction
Completed2,508——
NCT05376579
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
Active Secondary Progressive Multiple Sclerosis
Completed134——
NCT04593927
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
Secondary Progressive Multiple Sclerosis (SPMS)
Completed451—Mayzent
NCT04741789
Managed Access Programs for INC280, Capmatinib
Non-Small Cell Lung Cancer
NO_LONGER_AVAILABLE——Capmatinib